Multi-virus Antiviral Panel Assay
Viruses, as intracellular parasites of higher organisms, hijack and reprogram the host cell machinery to work for the benefit of the virus. Some of these host factors are strictly required for virus replication and they can be targeted for the development of antivirals. Some agents may display antiviral activity by targeting human factors needed for viral replication or to allow the virus to evade the immune system. RetroVirox offers a multi-viral panel to assess the antiviral efficacy of compounds under development for the treatment of non-viral indications. This panel may also be useful to identify broad-spectrum antiviral efficacy in compounds under development for a specific infectious agent.
Our antiviral panel is constantly adapted. As of 2019, the assay includes in vitro evaluation of antiviral efficacy against FOUR different viruses: Influenza A, HIV-1, HRSV and HCMV. These viruses are prototype members of four distinct genus: orthomyxovirus, retrovirus, orthoneumovirus and herpesvirus. This panel has been selected to include RNA and DNA viruses utilizing different mechanisms to replicate their genomes.
Antiviral assays are performed in permissive cell lines for each virus, and include cytotoxicity evaluations in the same cells used to perform the assays. Inclusion of additional viruses in our multi-virus panel is being evaluated and can be accommodated upon request. Panels against other specific viruses are also available at RetroVirox. Information about the Influenza Panel (20 strains) is available here
For additional information to evaluate the antiviral activity of lead compounds against a panel of five viruses call us at (858) 232-7919 or contact us at antivirals@retrovirox.com
To see more information about antiviral assays offered against other viruses click on the following links:
Human Respiratory Syncytial Virus (HRSV)
HIV Pseudoviruses for Neutralization Assays
